Leukapheresis Market - Top Companies and Manufacturers

In the News

• The U.S. Food and Drug Administration (FDA) has approved APHEXDATM (motixafortide) in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. BioLineRx Ltd., a commercial-stage biopharmaceutical company focused on certain cancers and rare diseases. Subcutaneous usage of APHEXDA is achieved through injectable administration.
• Kite, a Gilead Company (Nasdaq: GILD), announced that the FDA in the United States authorized a modification to the manufacturing process that will shorten the manufacturing time for Yescarta® (axicabtagene ciloleucel). It is estimated that Kite's median turnaround time (TAT) in the United States will drop from 16 days to 14 days with this approval. The time interval between leukapheresis, the collection of a patient's T cells, and product release is known as the median TAT. Manufacturing is a crucial phase in this process that gets a patient's cells ready for a unique one-time cell therapy injection.